Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06095128 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06095128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06095128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Recruiting
Start date
June 12, 2024
Completion date
July 9, 2027
Enrollment
60 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis